137 related articles for article (PubMed ID: 21197743)
1. [Management of metastatic colorectal cancer].
Tournigand C; Bengrine-Lefevre L; Chibaudel B; de Gramont A
Rev Prat; 2010 Oct; 60(8):1103-7. PubMed ID: 21197743
[TBL] [Abstract][Full Text] [Related]
2. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
Venook AP
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
[TBL] [Abstract][Full Text] [Related]
3. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
4. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
[TBL] [Abstract][Full Text] [Related]
5. The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer.
Van Cutsem E; Geboes K
Best Pract Res Clin Gastroenterol; 2007; 21(6):1089-108. PubMed ID: 18070705
[TBL] [Abstract][Full Text] [Related]
6. Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer.
Hendifar A; Tan CR; Annamalai A; Tuli R
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1051-61. PubMed ID: 24898788
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
8. [Antibody treatment in colorectal cancer--what the surgeon needs to know].
Thalheimer A; Illert B; Reimer P; Bueter M; Thiede A; Gasser M; Fein M; Waaga-Gasser AM; Meyer D
Zentralbl Chir; 2008 Apr; 133(2):101-6. PubMed ID: 18415895
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies in the treatment of advanced colorectal cancer.
Capdevila J; Saura C; Macarulla T; Casado E; Ramos FJ; Tabernero J
Eur J Surg Oncol; 2007 Dec; 33 Suppl 2():S24-34. PubMed ID: 17981431
[TBL] [Abstract][Full Text] [Related]
10. [Impact of mutational status of KRAS in the care of patients with colorectal cancer metastasis].
Assenat E; Ychou M
Bull Cancer; 2009 Dec; 96 Suppl():S41-6. PubMed ID: 20034869
[TBL] [Abstract][Full Text] [Related]
11. Targeted biotherapy in metastatic colorectal carcinoma: Current practice.
Cacheux W; Le Tourneau C; Baranger B; Mignot L; Mariani P
J Visc Surg; 2011 Feb; 148(1):12-8. PubMed ID: 21277276
[TBL] [Abstract][Full Text] [Related]
12. Targeting metastatic colorectal cancer in 2008: a long way from 5-FU.
Pohl A; Zhang W; Ning Y; Manegold PC; Lurje G; Lenz HJ
Oncology (Williston Park); 2008 Apr; 22(4):456-62; discussion 462-3, 467-8, 474 passim. PubMed ID: 18472617
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
14. [Anti-angiogenic treatment and colorectal cancer].
André T; Tournigand C; Abbas F; Louvet C; de Gramont A;
Bull Cancer; 2007 Jul; 94 Spec No():S211-9. PubMed ID: 17846007
[TBL] [Abstract][Full Text] [Related]
15. Precision Medicine in Metastatic Colorectal Cancer: Relevant Carcinogenic Pathways and Targets-PART 1: Biologic Therapies Targeting the Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor.
Weinberg BA; Hartley ML; Salem ME
Oncology (Williston Park); 2017 Jul; 31(7):539-48. PubMed ID: 28712098
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms and targeting of colorectal cancer.
Vanhoefer U
Semin Oncol; 2005 Dec; 32(6 Suppl 8):7-10. PubMed ID: 16360005
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on bevacizumab in metastatic colorectal cancer.
McCormack PL; Keam SJ
BioDrugs; 2008; 22(5):339-41. PubMed ID: 18778115
[TBL] [Abstract][Full Text] [Related]
18. First- and second-line therapy of metastatic colorectal cancer.
Terstriep S; Grothey A
Expert Rev Anticancer Ther; 2006 Jun; 6(6):921-30. PubMed ID: 16761936
[TBL] [Abstract][Full Text] [Related]
19. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).
Lawrence D; Maschio M; Leahy KJ; Yunger S; Easaw JC; Weinstein MC
J Med Econ; 2013 Dec; 16(12):1387-98. PubMed ID: 24102083
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenesis drug promising for metastatic colorectal cancer.
McCarthy M
Lancet; 2003 Jun; 361(9373):1959. PubMed ID: 12801743
[No Abstract] [Full Text] [Related]
[Next] [New Search]